Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clavogenix 625
- Development stage
- Unknown
- Lead developer
- Nilegenix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clavogenix 625 is a broad-spectrum antibiotic combination product marketed by Nilegenix, a generic pharmaceutical company based in India. It is a formulation of amoxicillin, a semi-synthetic beta-lactam antibiotic, and clavulanic acid, a beta-lactamase inhibitor. Amoxicillin works by binding to penicillin-binding proteins (PBPs) to inhibit the synthesis of the bacterial cell wall, leading to cell lysis. Clavulanic acid is included to overcome bacterial resistance mediated by beta-lactamase enzymes; it binds irreversibly to these enzymes, preventing them from degrading amoxicillin. This combination is used to treat a wide variety of bacterial infections, including those of the respiratory tract, urinary tract, skin, and soft tissues.
- Brand names
- Clavogenix 625Clavogenix625Clavogenix-625
- Other names
- Amoxicillin and Clavulanate PotassiumCo-amoxiclavAmoxicillin + Clavulanic Acid
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on Clavogenix 625.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clavogenix 625.